Odyssey voyages to Nasdaq with $304M IPO to fund autoimmune, inflammatory pipeline
Odyssey Therapeutics has become the latest biotech to voyage to the public markets via an upsized $304 million IPO this morning.
Odyssey Therapeutics has become the latest biotech to voyage to the public markets via an upsized $304 million IPO this morning.
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.